Originally developed for Type 2 diabetes, Glucagon-Like Peptide-1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) are receptor agonists that mimic the action of the hormones GLP-1 and GIP that are released by your gut after eating to help control blood sugars by stimulating insulin release in the pancreas and reducing another hormone called glucagon (which can increase our blood sugar), while increasing fullness to reduce appetite
Without it, your brain thinks your body is still hungry, causing you to eat more
To qualify, you generally need: A BMI of 30 or higher, or 27 or higher with a weight-related condition A prior trial of an oral weight-loss medication such as Qsymia or Contrave that did not work or that you cannot take At least 6 months of attempted weight loss through diet and exercise A prior authorization from your prescriber documenting medical necessity For type 2 diabetes, TRICARE coverage of GLP-1s like Ozempic and Mounjaro is more straightforward, though prior authorization may still apply
Key Points: Weight Loss : Tirzepatide users lose up to 20.9% of their body weight over 72 weeks, compared to 13.7% with Semaglutide
The appropriate choice between these two options is a clinical decision that your assigned provider should make based on your individual health profile
The gene set that is involved in the regulation of inflammatory signals, namely interleukin-1 and interleukin-6 pathways, were too down-regulated (Yoshihara et al
